Full Press Release Details
VP, General Counsel and Secretary
Novavax and Isconova
Novavax' Swedish Prospectus Approved
Rockville, MD (July 8, 2013)-/GlobeNewswire,
Inc. /-Novavax, Inc. (NASDAQ: NVAX) announced today the approval in Sweden of its prospectus related to its recommended offer to
acquire all outstanding shares and warrants (warrants series 2005-I and 2005-II) issued by Isconova AB (the "Offer"),
which was first communicated on June 4, 2013.
A prospectus regarding the Offer has been
approved and registered by the Swedish Financial Supervisory Authority (FSA). The prospectus has been announced today, and the
prospectus, together with the United States (U.S.) prospectus included as part of the registration statement filed by Novavax to
register the shares to be issued in the Offer, are available at Novavax' webpage (www.novavax.com), at Pareto hman
AB's webpage (www.paretosec.com), and at Isconova's webpage (www.isconova.com).
The prospectus will also be made available on the FSA webpage. Acceptance forms will also be made available at on the Novavax webpage
and the Pareto hman AB webpage. The prospectus, together with the U.S. prospectus, an information brochure and pre-printed
acceptance forms will be sent out to directly registered shareholders in Isconova's share register as of July 4, 2013. Isconova
shareholders considering the Offer should read the information in these documents because they will contain important information
regarding the Offer. The prospectus, the U.S. prospectus, the information brochure and acceptance forms can also be ordered from
Pareto hman AB by phone (+ 46 (0) 8 402 51 32). Isconova shareholders considering the Offer
may obtain copies of all documents filed with the U.S. Securities and Exchange Commission (SEC) regarding the Offer, free of charge,
at the SEC's website (www.sec.gov).
The acceptance period for the Offer commences
on July 9, 2013 and ends on July 30, 2013. Payment of consideration is expected to begin on August 9, 2013.
For more information, please contact Pareto
hman AB, phone (+ 46 (0) 8 402 51 32). This information was made public on July 8, 2013, at
Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage
biopharmaceutical company creating vaccines to address a broad range of infectious diseases worldwide. Using innovative recombinant
nanoparticle technology, as well as new and efficient manufacturing approaches, the company produces vaccine candidates to combat
diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections.
Novavax is committed to using its technology platform to create geographic-specific vaccine solutions and is therefore involved
in several international partnerships, including collaborations with Cadila Pharmaceuticals of India, LG Life Sciences of Korea
and PATH. Together, these organizations support Novavax' worldwide commercialization strategy and have the global reach to
create real and lasting change in the biopharmaceutical field. Additional information about Novavax is available on the company's
website, www.novavax.com.